News

Biogen & Ionis to collaborate again on treatments for SMA

Biogen & Ionis to collaborate again on treatments for SMABiogen and Ionis Pharmaceuticals have announced that they have entered into a new collaboration to identify new antisense oligonucleotide drugs for the treatment of SMA. These companies were responsible for the development and commercialisation of SPINRAZA (nusinersen), the first approved treatment for SMA. SPINRAZA is also an antisense oligonucleotide, which acts by increasing the amount of SMN protein produced.

Biogen will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialisation.

For more information:

Leave a Reply

Your email address will not be published. Required fields are marked *